Cryo Cell International (CCEL) Non-Current Deffered Revenue (2010 - 2026)

Cryo Cell International (CCEL) has 17 years of Non-Current Deffered Revenue data on file, last reported at $52.1 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 9.15% year-over-year to $52.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $52.1 million (up 9.15% YoY) and the FY2025 annual result came in at $51.0 million, up 9.49% from the prior year.
• Non-Current Deffered Revenue rose to $52.1 million in Q1 2026 per CCEL's latest filing, from $51.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $52.1 million in Q1 2026 and bottomed at $32.2 million in Q1 2022.
• The 5-year median for Non-Current Deffered Revenue is $42.6 million (2024), against an average of $42.4 million.
• The widest annual swing landed in 2023, when Non-Current Deffered Revenue climbed 15.84%; it then gained 9.15% in 2026.
• Tracing CCEL's Non-Current Deffered Revenue over 5 years: stood at $36.0 million in 2022, then advanced by 14.41% to $41.2 million in 2023, then grew by 13.04% to $46.6 million in 2024, then advanced by 9.49% to $51.0 million in 2025, then climbed by 2.21% to $52.1 million in 2026.
• Per Business Quant, the three latest CCEL Non-Current Deffered Revenue figures stand at $52.1 million (Q1 2026), $51.0 million (Q4 2025), and $49.8 million (Q3 2025).

Peer Comparison